NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $571,075 | -42.0% | 252,688 | -17.9% | 0.09% | -38.3% |
| Q3 2022 | $985,000 | -68.9% | 307,953 | -63.0% | 0.15% | -46.6% |
| Q2 2022 | $3,164,000 | -10.1% | 832,507 | +27.5% | 0.28% | -7.9% |
| Q1 2022 | $3,519,000 | +125.9% | 652,835 | +466.1% | 0.30% | +154.6% |
| Q4 2021 | $1,558,000 | -31.7% | 115,312 | -9.3% | 0.12% | -27.4% |
| Q3 2021 | $2,282,000 | -21.3% | 127,082 | -24.8% | 0.16% | -14.6% |
| Q2 2021 | $2,899,000 | -11.6% | 168,964 | +3.0% | 0.19% | -18.6% |
| Q1 2021 | $3,280,000 | +5.0% | 164,016 | -10.8% | 0.24% | +11.8% |
| Q4 2020 | $3,125,000 | +7.5% | 183,799 | +4.9% | 0.21% | +9.9% |
| Q3 2020 | $2,906,000 | -32.6% | 175,164 | -5.9% | 0.19% | -34.5% |
| Q2 2020 | $4,309,000 | -25.2% | 186,069 | -42.4% | 0.29% | -35.7% |
| Q1 2020 | $5,762,000 | -33.6% | 322,778 | -19.8% | 0.46% | -14.8% |
| Q4 2019 | $8,683,000 | +5.4% | 402,264 | -11.1% | 0.54% | +9.4% |
| Q3 2019 | $8,240,000 | +2.7% | 452,364 | +100.5% | 0.49% | +3.2% |
| Q2 2019 | $8,026,000 | -38.2% | 225,564 | -66.1% | 0.47% | -9.2% |
| Q2 2017 | $12,991,000 | +18.5% | 664,500 | +42.3% | 0.52% | -9.2% |
| Q1 2017 | $10,963,000 | +262.9% | 467,100 | +89.7% | 0.58% | +190.4% |
| Q4 2016 | $3,021,000 | -13.7% | 246,199 | +20.8% | 0.20% | -3.4% |
| Q3 2016 | $3,501,000 | +21.1% | 203,800 | +0.3% | 0.20% | -10.5% |
| Q2 2016 | $2,890,000 | +3.5% | 203,100 | 0.0% | 0.23% | +30.9% |
| Q1 2016 | $2,793,000 | +26.3% | 203,100 | +54.7% | 0.18% | -42.2% |
| Q4 2015 | $2,212,000 | +162.1% | 131,300 | +99.5% | 0.30% | +1217.4% |
| Q2 2014 | $844,000 | -26.7% | 65,800 | -30.8% | 0.02% | -17.9% |
| Q1 2014 | $1,152,000 | -20.1% | 95,054 | -25.2% | 0.03% | -83.8% |
| Q4 2013 | $1,442,000 | -59.6% | 127,054 | -62.8% | 0.17% | +78.4% |
| Q3 2013 | $3,572,000 | +25.1% | 341,854 | +38.3% | 0.10% | +31.1% |
| Q2 2013 | $2,855,000 | – | 247,154 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |